Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Study Finds no Clinically Meaningful Difference Between Alvotech’s AVT02 (adalimumab biosimilar) and AbbVie’s Humira® (adalimumab)

Jan 19, 2024

On 19 January 2024, an Alvotech-sponsored study, published in the Sage Journal, concluded on the basis of a “totality of evidence approach” that there was no clinically meaningful difference between Alvotech’s AVT02 (adalimumab biosimilar) and AbbVie’s Humira® (adalimumab). The study found that there were minor differences in a few physiochemical attributes, however, that did not impact the in vitro biologic activity and therefore this difference was ruled out and not considered clinically relevant.

On 23 February 2024, FDA approved Alvotech’s SIMLANDI® (AVT02) as an interchangeable high concentration, citrate-free biosimilar to AbbVie’s Humira® after which Alvotech’s U.S listed shares rose more than 12% to $18 in pre-market trading.